Last reviewed · How we verify
Granulomatosis with polyangiitis
Approved treatments
- Tavneos · Chemocentryx
Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response. - Mabthera · Roche
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction. - Tavneos · Chemocentryx
Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Granulomatosis with polyangiitis patent landscape — cliff calendar, originator estates, attackable patents
- Granulomatosis with polyangiitis treatment landscape brief
- Granulomatosis with polyangiitis treatment updates RSS
Frequently asked questions about Granulomatosis with polyangiitis
What drugs treat Granulomatosis with polyangiitis?
Tracked treatments include Tavneos, Mabthera.
What is the treatment for Granulomatosis with polyangiitis?
Standard treatment for Granulomatosis with polyangiitis includes Tavneos, Mabthera. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Granulomatosis with polyangiitis patent cliff · Granulomatosis with polyangiitis CI report
- Treatment: Tavneos · Chemocentryx
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Tavneos · Chemocentryx
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing